Kailera Therapeutics (KLRA) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Kailera Therapeutics (NASDAQ: KLRA):

• 5/13/2026 – Kailera Therapeutics was upgraded by Zacks Research to “hold”.
• 5/12/2026 – Kailera Therapeutics is now covered by TD Cowen. They set a “buy” rating and a $57.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $48.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics was upgraded by TD Cowen to “strong-buy”. They now have a $57.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $48.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 5/12/2026 – Kailera Therapeutics is now covered by Evercore Inc. They set an “outperform” rating on the stock.
• 4/25/2026 – Kailera Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Activity

In related news, Director Andrew T. Kaplan bought 8,398,438 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were bought at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Adam Koppel bought 1,562,500 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was bought at an average price of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director directly owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. This represents a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 10,460,938 shares of company stock worth $167,375,008 over the last 90 days.

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.